{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:35:34Z","timestamp":1788352534953,"version":"build-2803163510"},"reference-count":44,"publisher":"American Society of Hematology","issue":"16","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,27]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Previous studies have suggested that metformin has beneficial effects beyond its glucose-lowering properties, particularly in terms of its potential as an antineoplastic and cancer-preventive agent. In this study, we aimed to investigate the association between metformin use and the risk of myeloproliferative neoplasms (MPN). We conducted a population-based case-control study using Danish registers. Cases with MPN diagnosed between 2010 and 2018 were identified, and metformin use before the MPN diagnosis was ascertained. We compared metformin use among cases with MPN and an age- and sex-matched control group from the Danish general population to estimate age- and sex-adjusted odds ratios (ORs) and fully adjusted ORs (aORs) for the association between metformin use and risk of MPN. The study population included 3816 cases and 19\u2009080 controls. Overall, 7.0% of cases and 8.2% of controls were categorized as ever-users of metformin, resulting in an OR for MPN of 0.84 (95% confidence interval [CI], 0.73-0.96) and an aOR of 0.70 (95%\u00a0CI, 0.61-0.81). Long-term metformin use (\u22655 years) was more infrequent and comprised 1.1% of cases and 2.0% of controls, resulting in an OR of 0.57 (95%\u00a0CI, 0.42-0.79) and an aOR of 0.45 (95%\u00a0CI, 0.33-0.63). A dose-response relationship was observed when cumulative duration of treatment was analyzed, and this was consistent in stratified analyses of sex, age, and MPN subtypes. In conclusion, metformin use was associated with significantly lower odds of an MPN diagnosis, indicating its potential cancer-preventive effect. Given the retrospective design, causality cannot be inferred.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012266","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T13:45:48Z","timestamp":1715953548000},"page":"4478-4485","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Metformin use and risk of myeloproliferative neoplasms: a Danish population\u2013based case-control study"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6753-7051","authenticated-orcid":false,"given":"Daniel Tuyet","family":"Kristensen","sequence":"first","affiliation":[{"name":"1Department of Haematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark"},{"name":"2Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"},{"name":"3Department of Hematology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas Kiesbye","family":"\u00d8vlisen","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark"},{"name":"2Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6575-7686","authenticated-orcid":false,"given":"Lasse Hjort Kyneb","family":"Jakobsen","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0996-1812","authenticated-orcid":false,"given":"Marianne Tang","family":"Severinsen","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark"},{"name":"2Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise Hur","family":"Hannig","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine, Vejle Hospital, Vejle, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn","family":"Starklint","sequence":"additional","affiliation":[{"name":"5Department of Internal Medicine, Section for Hematology, Regional Hospital West, G\u00f8dstrup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6496-2941","authenticated-orcid":false,"given":"Morten Hagemann","family":"Hils\u00f8e","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Hospital of Southwest Jutland, Esbjerg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7209-7225","authenticated-orcid":false,"given":"Anders Pommer","family":"Vallentin","sequence":"additional","affiliation":[{"name":"7Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6282-5348","authenticated-orcid":false,"given":"Mette","family":"Brabrand","sequence":"additional","affiliation":[{"name":"8Department of Haematology, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3936-8032","authenticated-orcid":false,"given":"Hans Carl","family":"Hasselbalch","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4406-380X","authenticated-orcid":false,"given":"Tarec Christoffer","family":"El-Galaly","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark"},{"name":"2Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"},{"name":"10Department of Haematology, Haematology Research Unit, Odense University Hospital and Department of Clinical Research, University of Southern Denmark, Odense, Denmark"},{"name":"11Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2621-5432","authenticated-orcid":false,"given":"Anne Stidsholt","family":"Roug","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark"},{"name":"2Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"},{"name":"3Department of Hematology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"issue":"17","key":"2024082715203399900_bib1","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A\u00a0gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"2024082715203399900_bib2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024082715203399900_bib3","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"6","key":"2024082715203399900_bib4","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3324\/haematol.2015.141283","article-title":"Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies","volume":"101","author":"Zahr","year":"2016","journal-title":"Haematologica"},{"key":"2024082715203399900_bib5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2147\/CLEP.S113211","article-title":"Nationwide trends in glucose-lowering drug use, Denmark, 1999-2014","volume":"8","author":"Christensen","year":"2016","journal-title":"Clin Epidemiol"},{"issue":"9","key":"2024082715203399900_bib6","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/1940-6207.CAPR-13-0424","article-title":"Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders","volume":"7","author":"Gandini","year":"2014","journal-title":"Cancer Prev Res"},{"issue":"10","key":"2024082715203399900_bib7","article-title":"Metformin, an anti-diabetic drug to target leukemia","volume":"9","author":"Biondani","year":"2018","journal-title":"Front Endocrinol"},{"issue":"3","key":"2024082715203399900_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41419-017-0256-4","article-title":"Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms","volume":"9","author":"MacHado-Neto","year":"2018","journal-title":"Cell Death Dis"},{"issue":"12","key":"2024082715203399900_bib9","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.exphem.2016.08.005","article-title":"Metformin inhibits JAK2V617F activity in MPN cells by activating AMPK and PP2A complexes containing the B56\u03b1 subunit","volume":"44","author":"Kawashima","year":"2016","journal-title":"Exp Hematol"},{"issue":"suppl 7","key":"2024082715203399900_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1403494810387965","article-title":"The Danish civil registration system","volume":"39","author":"Pedersen","year":"2011","journal-title":"Scand J Public Health"},{"issue":"4","key":"2024082715203399900_bib11","first-page":"441","article-title":"The Danish civil registration system. A cohort of eight million persons","volume":"53","author":"Pedersen","year":"2006","journal-title":"Dan Med Bull"},{"issue":"suppl 7","key":"2024082715203399900_bib12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish national patient register","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand J Public Health"},{"issue":"17","key":"2024082715203399900_bib13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish national patient registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"issue":"8","key":"2024082715203399900_bib14","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2147\/CLEP.S99462","article-title":"The Danish national chronic myeloid neoplasia registry","volume":"8","author":"Bak","year":"2016","journal-title":"Clin Epidemiol"},{"issue":"3","key":"2024082715203399900_bib15","article-title":"Data resource profile: the Danish national prescription registry","volume":"46","author":"Potteg\u00e5rd","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"suppl 7","key":"2024082715203399900_bib16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish national prescription registry","volume":"39","author":"Wallach Kildemoes","year":"2011","journal-title":"Scand J Public Health"},{"issue":"suppl 7","key":"2024082715203399900_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/1403494810394715","article-title":"Danish education registers","volume":"39","author":"Jensen","year":"2011","journal-title":"Scand J Public Health"},{"key":"2024082715203399900_bib18","author":"Swerdlow","year":"2008","edition":"4th ed"},{"issue":"20","key":"2024082715203399900_bib19","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"2024082715203399900_bib20","author":"Lash","year":"2021","edition":"4th ed"},{"issue":"5","key":"2024082715203399900_bib21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"issue":"suppl 1","key":"2024082715203399900_bib22","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.canep.2015.08.003","article-title":"European code against cancer 4th edition: medical exposures, including hormone therapy, and cancer","volume":"39","author":"Friis","year":"2015","journal-title":"Cancer Epidemiol"},{"issue":"suppl 1","key":"2024082715203399900_bib23","doi-asserted-by":"crossref","first-page":"10991","DOI":"10.1182\/blood-2022-167640","article-title":"Metformin use and incidence of cancer: a large retrospective cohort study of U.S. veterans","volume":"140","author":"Abdallah","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024082715203399900_bib24","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S2352-3026(14)00037-4","article-title":"Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study","volume":"2","author":"Chang","year":"2015","journal-title":"Lancet Haematol"},{"issue":"5","key":"2024082715203399900_bib25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2024082715203399900_bib26","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/ejh.13841","article-title":"Healthcare resource utilization in patients with myeloproliferative neoplasms: a Danish nationwide matched cohort study","volume":"109","author":"Christensen","year":"2022","journal-title":"Eur J Haematol"},{"issue":"suppl 1","key":"2024082715203399900_bib27","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood-2021-151077","article-title":"Final results of the fibromet trial: an open label phase II study to evaluate metformin effects on bone marrow fibrosis and disease progression in primary myelofibrosis patients","volume":"138","author":"Campos","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2024082715203399900_bib28","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1097\/HS9.0000000000000645","article-title":"New perspectives of interferon-alpha2 and inflammation in treating Philadelphia-negative chronic myeloproliferative neoplasms","volume":"5","author":"Hasselbalch","year":"2021","journal-title":"Hemasphere"},{"issue":"16","key":"2024082715203399900_bib29","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2020008109","article-title":"The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms","volume":"137","author":"Hasselbalch","year":"2021","journal-title":"Blood"},{"issue":"14","key":"2024082715203399900_bib30","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/bloodadvances.2023009784","article-title":"Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study","volume":"7","author":"Tuyet Kristensen","year":"2023","journal-title":"Blood Adv"},{"issue":"18","key":"2024082715203399900_bib31","doi-asserted-by":"crossref","first-page":"18889","DOI":"10.1002\/cam4.6528","article-title":"Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia","volume":"12","author":"Podoltsev","year":"2023","journal-title":"Cancer Med"},{"issue":"8","key":"2024082715203399900_bib32","doi-asserted-by":"crossref","first-page":"e71583","DOI":"10.1371\/journal.pone.0071583","article-title":"Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review","volume":"8","author":"Franciosi","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"2024082715203399900_bib33","doi-asserted-by":"crossref","DOI":"10.2144\/fsoa-2019-0053","article-title":"Anticancer activity of metformin: a systematic review of the literature","volume":"5","author":"Aljofan","year":"2019","journal-title":"Future Sci OA"},{"issue":"4","key":"2024082715203399900_bib34","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(15)00565-3","article-title":"Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial","volume":"17","author":"Higurashi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"2024082715203399900_bib35","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/cen.13830","article-title":"The benefits of adding metformin to tamoxifen to protect the endometrium\u2014a randomized placebo-controlled trial","volume":"89","author":"Davis","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"6","key":"2024082715203399900_bib36","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/s41416-023-02204-2","article-title":"Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?","volume":"128","author":"Lord","year":"2023","journal-title":"Br J Cancer"},{"issue":"20","key":"2024082715203399900_bib37","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.2022.6147","article-title":"Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA.32 randomized clinical trial","volume":"327","author":"Goodwin","year":"2022","journal-title":"JAMA"},{"issue":"11","key":"2024082715203399900_bib38","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.3324\/haematol.2019.229039","article-title":"Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?","volume":"104","author":"Hasselbalch","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"2024082715203399900_bib39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"issue":"11","key":"2024082715203399900_bib40","doi-asserted-by":"crossref","first-page":"e163968","DOI":"10.1172\/JCI163968","article-title":"Obesity-induced inflammation exacerbates clonal hematopoiesis","volume":"133","author":"Pasupuleti","year":"2023","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"2024082715203399900_bib41","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/eurpub\/ckad024","article-title":"Changes in adult obesity prevalence in Denmark, 1987-2021: age\u2013period\u2013cohort analysis of nationally representative data","volume":"33","author":"Schramm","year":"2023","journal-title":"Eur J Public Health"},{"key":"2024082715203399900_bib42","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2147\/CLEP.S214909","article-title":"Validity of ICD-10 diagnoses of overweight and obesity in Danish hospitals","volume":"11","author":"Gribsholt","year":"2019","journal-title":"Clin Epidemiol"},{"issue":"7","key":"2024082715203399900_bib43","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/ijc.28492","article-title":"Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women\u2019s Health Study cohort","volume":"134","author":"Leal","year":"2014","journal-title":"Int J Cancer"},{"issue":"1","key":"2024082715203399900_bib44","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1097\/HS9.0000000000000327","article-title":"Modifiable lifestyle and medical risk factors associated with myeloproliferative neoplasms","volume":"4","author":"Duncombe","year":"2020","journal-title":"Hemasphere"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/16\/4478\/2239642\/blooda_adv-2023-012266-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/16\/4478\/2239642\/blooda_adv-2023-012266-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T15:21:07Z","timestamp":1724772067000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/16\/4478\/516127\/Metformin-use-and-risk-of-myeloproliferative"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":44,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012266","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]}}}